ARO-HSD explained

ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease.^{[1] [2] [3] [4]} The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion.^[5]

Notes and References

1. Mak . Lung-Yi . Gane . Ed . Schwabe . Christian . Yoon . Ki Tae . Heo . Jeong . Scott . Russell . Lee . Jeong-Hoon . Lee . Jung Il . Kweon . Young Oh . Weltman . Martin . Harrison . Stephen A. . Neuschwander-Tetri . Brent A. . Cusi . Kenneth . Loomba . Rohit . Given . Bruce D. . Christianson . Dawn R. . Garcia-Medel . Eric . Yi . Min . Hamilton . James . Yuen . Man-Fung . A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis . Journal of Hepatology . April 2023 . 78 . 4 . 684–692 . 10.1016/j.jhep.2022.11.025. 36513186 . 254561720 .
2. Smati . Sarra . Canivet . Clémence M. . Boursier . Jérôme . Cariou . Bertrand . Voies thérapeutiques dans l'hépatopathie stéatosique métabolique . Médecine des Maladies Métaboliques . May 2023 . 17 . 3 . 261–270 . 10.1016/j.mmm.2023.03.007. 257839829 . free .
3. Ajmera . Veeral . Loomba . Rohit . Advances in the genetics of nonalcoholic fatty liver disease . Current Opinion in Gastroenterology . May 2023 . 39 . 3 . 150–155 . 10.1097/MOG.0000000000000927. 37144531 . 10167543 .
4. Lindén . Daniel . Romeo . Stefano . Therapeutic opportunities for the treatment of NASH with genetically validated targets . Journal of Hepatology . October 2023 . 79 . 4 . 1056–1064 . 10.1016/j.jhep.2023.05.007. 37207913 . 258777103 .
5. News: Dealmakers . Biopharma . Buy buy RNAi . 3 December 2023 . Biopharma Dealmakers . 1 June 2022 . en . 10.1038/d43747-022-00169-4.